- Home
- AAL vs MDGL Comparison
AAL vs MDGL Comparison
Compare AAL & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AAL | MDGL |
|---|---|---|
| Founded | 1930 | 2011 |
| Country | United States | United States |
| Employees | 133700 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 10.0B |
| IPO Year | 2004 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AAL | MDGL |
|---|---|---|
| Price | $11.20 | $435.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 14 |
| Target Price | $16.58 | ★ $637.92 |
| AVG Volume (30 Days) | ★ 55.2M | 344.4K |
| Earning Date | 04-27-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $54,633,000,000.00 | $180,133,000.00 |
| Revenue This Year | $10.06 | $58.70 |
| Revenue Next Year | $5.67 | $46.88 |
| P/E Ratio | $69.29 | ★ N/A |
| Revenue Growth | ★ 0.78 | N/A |
| 52 Week Low | $8.50 | $265.00 |
| 52 Week High | $16.50 | $615.00 |
Technical Indicators
Market Signals| Indicator | AAL | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 29.45 | 39.32 |
| Support Level | $10.76 | $410.78 |
| Resistance Level | $11.96 | $452.22 |
| Average True Range (ATR) | 0.58 | 19.94 |
| MACD | -0.20 | 0.97 |
| Stochastic Oscillator | 3.45 | 23.73 |
Price Performance
Historical ComparisonAbout AAL American Airlines Group Inc.
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Dallas/Fort Worth, Charlotte, Chicago, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest average fleet of US legacy carriers.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.